Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immunogen Inc (IMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,491,378
  • Shares Outstanding, K 133,040
  • Annual Sales, $ 115,450 K
  • Annual Income, $ -96,010 K
  • 36-Month Beta 2.14
  • Price/Sales 12.10
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.47 +23.40%
on 06/11/18
11.99 -2.63%
on 06/01/18
+1.41 (+13.73%)
since 05/21/18
3-Month
9.47 +23.40%
on 06/11/18
13.41 -12.90%
on 03/26/18
-0.82 (-6.56%)
since 03/21/18
52-Week
4.80 +143.33%
on 11/03/17
13.41 -12.90%
on 03/26/18
+5.66 (+94.02%)
since 06/21/17

Most Recent Stories

More News
ImmunoGen Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the underwriters of its previously...

IMGN : 11.68 (+4.19%)
ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer

With ImmunoGen's (IMGN) lead pipeline candidate, mirvetuximab soravtansine getting Fast Track designation in the United States, its development and review are likely to get expedited.

AGLE : 10.48 (-2.78%)
MRK : 61.18 (-0.16%)
IMGN : 11.68 (+4.19%)
RHHBY : 27.0900 (unch)
ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration...

IMGN : 11.68 (+4.19%)
Clovis Oncology has the Best Relative Performance in the Biotechnology Industry (CLVS , IMGN , NTRA , MRTX, EBS )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

NTRA : 14.04 (-3.64%)
CLVS : 47.33 (-2.35%)
IMGN : 11.68 (+4.19%)
MRTX : 52.40 (+1.75%)
The Brian Bolan Show!

The Brian Bolan Show!

NFLX : 415.44 (-0.32%)
LSCC : 6.33 (-1.25%)
IMGN : 11.68 (+4.19%)
DOCU : 57.59 (-7.80%)
TAL : 39.37 (-1.03%)
FSCT : 35.28 (+2.29%)
ImmunoGen Announces Closing of Public Offering of Common Stock

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced...

IMGN : 11.68 (+4.19%)
Immunogen Inc Set to Possibly Rebound After Yesterday's Selloff of 8.03%

Immunogen Inc (NASDAQ:IMGN) traded in a range yesterday that spanned from a low of $10.25 to a high of $11.70. Yesterday, the shares fell 8.0%, which took the trading range below the 3-day low of $10.53...

IMGN : 11.68 (+4.19%)
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an upsized underwritten...

IMGN : 11.68 (+4.19%)
Shares of Seres Therapeuti Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (MCRB , CYTK , IMGN , ARRY , PTLA )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

CYTK : 8.20 (-2.38%)
MCRB : 9.04 (-5.34%)
IMGN : 11.68 (+4.19%)
ImmunoGen Announces Proposed Public Offering of Common Stock

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject...

IMGN : 11.68 (+4.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More Share

Trade IMGN with:

Business Summary

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended...

See More

Key Turning Points

2nd Resistance Point 12.20
1st Resistance Point 11.94
Last Price 11.68
1st Support Level 11.30
2nd Support Level 10.92

See More

52-Week High 13.41
Last Price 11.68
Fibonacci 61.8% 10.12
Fibonacci 50% 9.10
Fibonacci 38.2% 8.09
52-Week Low 4.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar